Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy - PubMed (original) (raw)

Clinical Trial

Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy

Michael F H Schocke et al. Neuroimage. 2003 Oct.

Abstract

To evaluate biochemical changes in contrast-enhancing multiple sclerosis (MS) lesions, we examined 14 patients with relapsing-remitting MS at acute clinical exacerbation with the help of contrast-enhanced magnetic resonance imaging (MRI) and 1H magnetic resonance spectroscopic imaging (1H MRSI). Using a 1.5-tesla MR system (Magnetom Vision, Siemens, Germany), we followed 29 contrast-enhancing and 24 nonenhancing MS lesions as well as normal-appearing white matter (NAWM) before and during high-dose methylprednisolone (HDMP) therapy. Metabolite ratios of N-acetylaspartate (NAA), choline (Cho), creatine (Cr), and lactate (Lac) were calculated. A transient decrease in contrast enhancement under HDMP therapy was observed. Both groups of MS lesions showed significantly decreased NAA to Cr ratios compared to NAWM with no changes in time. Baseline 1H MRSI revealed significantly increased Cho to Cr ratios in the contrast-enhancing MS lesions (1.13 +/- 0.25) compared to the nonenhancing MS lesions (0.85 +/- 0.26, P < 0.001) and NAWM (0.97 +/- 0.22, P = 0.015). Both the contrast-enhancing and the nonenhancing MS lesions exhibited a significant increase in Cho to Cr ratios from the second to the third 1H MRSI. We identified resonances of lactate in both groups of MS lesions and NAWM without any significant group differences or changes over time. 1H MRSI provides additional information that help to estimate macrophages' activity, cell membrane activation, and neuronal impairment within MS lesions. We believe that combined contrast-enhanced MRI and 1H MRSI may help to further investigate inflammatory processes within active MS lesions and should be employed more frequently to the research on therapy effects in MS.

PubMed Disclaimer

Cited by

Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.
Vallée A, Lecarpentier Y, Guillevin R, Vallée JN. Vallée A, et al. Int J Mol Sci. 2018 Apr 16;19(4):1212. doi: 10.3390/ijms19041212. Int J Mol Sci. 2018. PMID: 29659554 Free PMC article. Review.
11C-PK11195 plasma metabolization has the same rate in multiple sclerosis patients and healthy controls: a cross-sectional study.
de Souza AM, Pitombeira MS, de Souza LE, Marques FLN, Buchpiguel CA, Real CC, de Paula Faria D. de Souza AM, et al. Neural Regen Res. 2021 Dec;16(12):2494-2498. doi: 10.4103/1673-5374.313062. Neural Regen Res. 2021. PMID: 33907039 Free PMC article.
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
Albanese M, Zagaglia S, Landi D, Boffa L, Nicoletti CG, Marciani MG, Mandolesi G, Marfia GA, Buttari F, Mori F, Centonze D. Albanese M, et al. J Neuroinflammation. 2016 Feb 10;13:36. doi: 10.1186/s12974-016-0502-1. J Neuroinflammation. 2016. PMID: 26863878 Free PMC article.
Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions.
Nijland PG, Molenaar RJ, van der Pol SM, van der Valk P, van Noorden CJ, de Vries HE, van Horssen J. Nijland PG, et al. Acta Neuropathol Commun. 2015 Dec 4;3:79. doi: 10.1186/s40478-015-0261-8. Acta Neuropathol Commun. 2015. PMID: 26637184 Free PMC article.
Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy.
Mechtcheriakov S, Schocke M, Kugener A, Graziadei IW, Mattedi M, Hinterhuber H, Vogel W, Marksteiner J. Mechtcheriakov S, et al. Neuroradiology. 2005 Jan;47(1):27-34. doi: 10.1007/s00234-004-1298-8. Epub 2005 Jan 18. Neuroradiology. 2005. PMID: 15655660

Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy - PubMed (original) (raw)